Childhood psoriasis is a common chronic disease that may have devastating physical and psychosocial consequences. Most children are treated with topical agents, including corticosteroids, coal tars, anthralin, calcipotriene, and tazarotene. For moderate to severe cases, systemic treatments such as phototherapy, methotrexate, cyclosporine, and acitretin are used. In the last 10 years, biologics with an emphasis on tumor necrosis factor-α inhibitors have been shown to be effective without the toxicities associated with older systemic treatments. Future studies are needed that focus on the efficacy and safety of these treatments in children.
LehmanJ.S.Congenital psoriasis: case report and literature review. Pediatr Dermatol.2008; 25: 332–8.
6.
NyforsA., LomholtL.Psoriasis in children. Br J Dermatol.1975; 72: 437–42.
7.
KumarB., JainR., SandhuK., KaurI., HandaS.Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol.2004; 43(9): 654–8.
8.
Al-FouzanA.S., NandaA.A survey of childhood psoriasis in Kuwait. Pediatr Dermatol.1994; 11(2): 116–9.
9.
DuffyD.L., SpelmanL.S., MartinN.G.Psoriasis in Australian twins. J Am Acad Dermatol.1993; 29(3): 428–34.
10.
BrandrupF., HolmN., GrunnetN., HenningsenK., HansenH.E.Psoriasis in monozygotic twins: variations in expression with identical gene constitution. Acta Dermatol Venereol.1982; 62: 229–36.
11.
FarberE., NallM., WatsonW.Natural history of psoriasis in 61 twin pairs. Arch Dermatol.1974; 109: 207–11.
12.
KamiliQ., MenterA.Genetics of psoriasis and psoriatic arthritis. Psoriasis Forum.2009; 15(1): 8–11.
13.
MarcouxD., ProstY.Pediatric psoriasis revisited. J Cutan Med Surg.2002; 6(3): 22–8.
14.
LowesM.A., BowcockA.M., KruegerJ.G.Pathogenesis and therapy of psoriasis. Nature.2007; 445(7130): 866–73.
15.
WilsonJ.K., Al-SuwaidanS.N., KrowchukD., FeldmanS.R.Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy?Pediatr Dermatol.2003; 20(1): 11–5.
16.
LiaoP.B., RubinsonR., HowardR.Annular pustular psoriasis: Most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol.2002; 19(1): 19–25.
GottliebA.B., KormanN.J., GordonK.B.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol.2008; 58: 851–64.
19.
GelfandJ.M., TroxelA.B., LewisJ.D., KurdS.K., ShinD.B., WangX.The risk of mortality in patients with psoriasis: results from a population based study. Arch Dermatol.2007; 143: 1493–9.
20.
GottliebA.B., DannF., MenterA.Psoriasis and the metabolic syndrome. J Drugs Dermatol.2008; 7(6): 563–72.
21.
GelfandJ.M., NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B.Risk of myocardial infarction in patients with psoriasis. JAMA.2006; 296(14): 1735–41.
22.
MenterA., GottliebA.B., FeldmanS.R., GelfandJ.M., GordonK.B., GottliebA.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol.2008; 58(5): 826–50.
23.
GelfandJ.M., ShinD.B., NeimannA.L., WangX., MargolisD.J., TroxelA.B.The risk of lymphoma in patients with psoriasis. J Invest Dermatol.2006; 126(10): 2194–201.
24.
KimbalA.B., JacobsonC., WeissS., VreelandM.G., WuY.The psychosocial burden of psoriasis. Am J Clin Dermatol.2005; 6(6): 383–92.
25.
LevensonJ.L.Psychiatric issues in dermatology, part 1: Atopic dermatitis and psoriasis. Primary Psychiatry.2008; 15(7): 35–8.
26.
GuptaM.A., GuptaA.K.Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol.1998; 139: 846–50.
27.
LewkowiczD., GottliebA.B.Pediatric psoriasis and psoriatic arthritis. Dermatol Ther.2004; 17: 364–75.
28.
ReichertU., JacquesY., GrangeretM., GrangeretM., SchmidtR.Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J Invest Dermatol.1985; 84(2): 130–4.
29.
ZvulunovA., AnisfeldA., MetzkerA.Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol.1994; 33(11): 808–10.
30.
GuerrierC.J., PorterD.I.An open assessment of 0.1% dithranol in a 17% urea base (Psoradrate 0.1%) in the treatment of psoriasis of children. Curr Med Res Opin.1983; 8(6): 446–50.
31.
JensenA.M., LladoM.B., SkovL., HansenE.R., LarsenJ.K., BaadsgaardO.Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol.1998; 139(6): 984–91.
32.
AshcroftD.M., PoA.L., WilliamsH.C., GriffithsC.E.Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ.2000; 320(7240): 963–7.
33.
LebwohlM., SiskinS.B., EpinetteW., BrenemanD., FunicellaD., KalbR.A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol.1996; 35(2): 268–9.
DarleyC.R., CunliffeW.J., GreenC.M., HutchinsonP.E., KlaberM.R., DownesN.Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol.1996; 135(3): 390–3.
36.
DuvicM.Pharmacologic profile of tazarotene. Cutis.1998; 61(2): 22–6.
37.
WeinsteinG.D.Tazarotene gel: efficacy and safety in plaque psoriasis. J Am Acad Dermatol.1997; 37(2): 33–8.
38.
TanghettiE.A.An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis.2000; 66(6): 4–11.
39.
CordoroK.M.Management of childhood psoriasis. Adv Dermatol.2008; 24: 125–69.
40.
SteeleJ.A., ChoiC., KwongP.C.Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol.2005; 53(4): 713–6.
41.
BruneA., MillerD.W., LinP., Cotrim-RussiD., PallerA.S.Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol.2007; 24(1): 76–80.
IbbotsonS.H., BilslandD., CoxN.H., DaweR.S., DiffeyB., EdwardsC.An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol.2004; 151(2): 283–97.
WolffK.Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol.1990; 122(36): 117–25.
46.
SpulsP.I., HadiS., RiveraL., LebwohlM.Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat.2003; 14(2): 21–5.
FeldmanS.R., MellenB.G., HousmanT.S., FitzpatrickR.E., GeronemusR.G., FriedmanP.M.Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol.2002; 46(6): 900–6.
49.
PahlajaniN., KatzB.J., LozanoA.M., MurphyF., GottliebA.Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study. Pediatr Dermatol.2005; 22(2): 161–5.
50.
Del RossoJ., FriedlanderS.Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol.2005; 53(1): S50–8.
51.
DadlaniC., OrlowS.J.Treatment of children and adolescents with methotrexate, cyclosporine and etanercept: review of the dermatologic and rheumatologic literature. J Am Acad Dermatol.2005; 52: 316–40.
52.
KalbR., StroberB., WeinsteinG., LebwohlM.Methotrexate and psoriasis: 2009 national psoriasis foundation consensus conference. J Am Acad Dermatol.2009; 60: 824–37.
53.
MenterA., KormanN.J., ElmetsC.A., FeldmanS.R., GelfandJ.M., GordonK.B.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol.2009; 61(3): 451–85.
54.
PaulC.F., HoV.C., McGeownC., ChristophersE., SchmidtmannB., GuillaumeJ.C.Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-year cohort study. J Invest Dermatol.2003; 120: 211–16.
55.
PereiraT.M., VieiraA.P., FernandesJ.C., Sousa-BastoA.Cyclosporine A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol.2006; 20: 651–6.
56.
BrecherA.R., OrlowS.J.Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol.2003; 49(2): 171–82.
57.
BergerE., GottliebA.B.Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol.2007; 7(4): 434–44.
58.
Duchet-NiedziolkaP., CoutsinosZ., HanslikT., LaunayO.Anti-TNF-alpha therapy and vaccination of adults. Joint Bone Spine.2007; 74(6): 563–5.
59.
BorteS., LiebertU.G., BorteM., SackU.Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology.2009; 48: 144–8.
60.
MeaseP.J., RichlinC.T., MartinR.W., GottliebA.B., BaumgartnerS.W., BurgeD.J.Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol.2004; 31(7): 1356–61.
61.
FominI., CaspiD., LevyV.Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF-α blockers. Ann Rheum Dis.2006; 65: 191–4.
62.
KaineJ.L., KivitzA.J., BirbaraC., LuoA.Y.Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol.2007; 34(2): 272–9.
PapoutsakiM., CostanzoA., MazzottaA.Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol.2006; 154(1): 181–3.
66.
KressD.W.Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol.2006; 54: S126–8.
67.
HawrotA.C., MetryD.W., TheosA.J., LevyM.L.Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol.2006; 23(1): 67–71.
68.
PallerA.S., SiegfriedE.C., LangleyR.G., GottliebA.B., Pa riserD., LandellsI.Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med.2008; 358: 241–51.
MenterM.A., CushJ.M.Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol.2004; 21(1): 87–8.
73.
FarnsworthN.N., GeorgeS.J., HsuS.Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J.2005; 11(3): 11.
LovellD.J., RupertoN., GoodmanS., ReiffA., JungL., JarosovaK.Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med.2008; 359(8): 810–20.
